HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion in assets under management.
Other new investors who participated in the round include B Capital Group, and a slew of Greater China-based investment firms including Sherpa Healthcare Partners, Maison Capital, Trinity Innovation Fund, Grand Mount, and Hong Kong’s HSTP Venture Fund.
